Development of radiotracers for oncology - the interface with pharmacology

被引：45

作者：

Sharma, Rohini ^{[1
,2
]}

Aboagye, Eric ^{[1
]}

机构：

[1] Univ London Imperial Coll Sci Technol & Med, Comprehens Canc Imaging Ctr, London W12 ONN, England

[2] Univ London Imperial Coll Sci Technol & Med, Div Expt Med, London W12 ONN, England

来源：

BRITISH JOURNAL OF PHARMACOLOGY | 2011年 / 163卷 / 08期

基金：

英国工程与自然科学研究理事会;

关键词：

positron emission tomography (PET); radioisotope; drug development; radiopharmaceutical; POSITRON-EMISSION-TOMOGRAPHY; MONITORING TUMOR RESPONSE; IN-VIVO DETECTION; CELL LUNG-CANCER; BREAST-CANCER; FDG-PET; PROSTATE-CANCER; IMAGING PROLIFERATION; DRUG DEVELOPMENT; CHOLINE KINASE;

D O I：

10.1111/j.1476-5381.2010.01160.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

There is an increasing role for positron emission tomography (PET) in oncology, particularly as a component of early phase clinical trials. As a non-invasive functional imaging modality, PET can be used to assess both pharmacokinetics and pharmacodynamics of novel therapeutics by utilizing radiolabelled compounds. These studies can provide crucial information early in the drug development process that may influence the further development of novel therapeutics. PET imaging probes can also be used as early biomarkers of clinical response and to predict clinical outcome prior to the administration of therapeutic agents. We discuss the role of PET imaging particularly as applied to phase 0 studies and discuss the regulations involved in the development and synthesis of novel radioligands. The review also discusses currently available tracers and their role in the assessment of pharmacokinetics and pharmacodynamics as applied to oncology.

引用

页码：1565 / 1585

页数：21

共 148 条

[1] Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors [J].